US Broker Ratings

QuidelOrtho Corporation (QDEL) Stock Analysis: Exploring a 39.66% Potential Upside for Savvy Investors

QuidelOrtho Corporation (NASDAQ: QDEL), a significant player in the healthcare sector, particularly within the medical devices industry, presents an intriguing opportunity for investors seeking exposure to diagnostic testing solutions. With..

PROCEPT BioRobotics (PRCT) Stock Analysis: Exploring a 79.78% Potential Upside in the Medical Device Sector

PROCEPT BioRobotics Corporation (NASDAQ: PRCT), a key player in the medical device sector, is capturing the attention of investors with its innovative solutions in urology. Headquartered in San Jose, California,..

Kymera Therapeutics, Inc. (KYMR) Stock Analysis: Unveiling the Potential Upside Amidst a Robust Buy Rating Consensus

For investors looking to tap into the dynamic world of biotechnology, Kymera Therapeutics, Inc. (NASDAQ: KYMR) presents an intriguing opportunity. With a market capitalization of $4.18 billion, this clinical-stage biopharmaceutical..

Acadia Healthcare Company, Inc. (ACHC) Stock Analysis: Exploring a 24.87% Upside Potential

Acadia Healthcare Company, Inc. (NASDAQ: ACHC), a leader in the behavioral healthcare sector, presents a compelling opportunity for investors seeking exposure to the healthcare industry. With a market capitalization of..

Progyny, Inc. (PGNY) Stock Analysis: Exploring a 31.89% Potential Upside in the Healthcare Sector

Progyny, Inc. (PGNY), a prominent player in the healthcare sector, stands out with its innovative fertility and family-building benefits solutions. Headquartered in New York, the company has carved a niche..

GoodRx Holdings, Inc. (GDRX) Stock Analysis: Unpacking a 25% Potential Upside in Healthcare Innovation

GoodRx Holdings, Inc. (NASDAQ: GDRX) stands at an intriguing juncture for investors seeking opportunities in the dynamic healthcare sector. With a market capitalization of $1.4 billion, this U.S.-based company has..

Beam Therapeutics Inc. (BEAM) Stock Analysis: A Promising Upside of 94.13% Amidst Biotechnology Innovation

For investors seeking opportunities in the biotechnology sector, Beam Therapeutics Inc. (NASDAQ: BEAM) presents a compelling prospect. With a significant market capitalization of $2.42 billion and a strategic focus on..

Celldex Therapeutics, Inc. (CLDX) Stock Analysis: A Biotech Gem with 114.78% Potential Upside

For investors with a keen eye on the biotechnology sector, Celldex Therapeutics, Inc. (NASDAQ: CLDX) presents a compelling opportunity. With a market capitalization of $1.74 billion, this U.S.-based biopharmaceutical company..

AtriCure, Inc. (ATRC) Stock Analysis: Unpacking a 43.39% Potential Upside in the Healthcare Sector

AtriCure, Inc. (NASDAQ: ATRC) is capturing the attention of investors with its promising potential for significant upside, amid a 17.10% revenue growth and a robust Buy rating consensus. With a..

Certara, Inc. (CERT) Investor Outlook: Unpacking the 17.41% Potential Upside in the Healthcare Sector

Certara, Inc. (NASDAQ: CERT), a pivotal player in the healthcare sector, operates at the intersection of technology and biosimulation. With a market capitalization of $1.96 billion, Certara is a noteworthy..

Apogee Therapeutics, Inc. (APGE) Stock Analysis: A High-Stakes Bet in Biotechnology with 135% Upside Potential

Apogee Therapeutics, Inc. (NASDAQ: APGE), a clinical-stage biotechnology firm, has captured investor attention with its promising pipeline of biologics aimed at treating a range of inflammatory and immunology-related conditions. With..

Schrodinger, Inc. (SDGR) Stock Analysis: Exploring a 40% Upside Potential

Schrödinger, Inc. (NASDAQ: SDGR), standing at the intersection of technology and healthcare, presents a compelling opportunity for investors who are keen on groundbreaking innovation in drug development and materials science...

Amicus Therapeutics (FOLD) Stock Analysis: Exploring a 100% Upside Potential

Investors eyeing the biotechnology sector may find Amicus Therapeutics, Inc. (NASDAQ: FOLD) a compelling consideration, particularly given the significant upside potential reflected in recent analyst ratings. As a key player..

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Navigating a 9.95% Potential Upside Amidst Biotech Volatility

PTC Therapeutics, Inc. (NASDAQ: PTCT), a stalwart in the biotechnology sector, commands attention with its robust pipeline of treatments for rare disorders. As a healthcare company headquartered in Warren, New..

IDEAYA Biosciences, Inc. (IDYA) Stock Analysis: Unpacking a 73% Potential Upside

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is capturing the spotlight in the biotechnology sector with a compelling narrative centered around its precision medicine oncology focus. Headquartered in South San Francisco, California,..

Alignment Healthcare, Inc. (ALHC) Stock Analysis: Strong Buy Ratings Amid Robust Revenue Growth

Alignment Healthcare, Inc. (NASDAQ: ALHC) stands out in the Healthcare sector, particularly in the Healthcare Plans industry, with its consumer-focused platform dedicated to providing tailored healthcare services for seniors through..

Ultragenyx Pharmaceutical Inc. (RARE): Exploring a Potential 186% Upside Amidst Strong Buy Ratings

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a trailblazer in the biotech sector, is capturing investor attention with a remarkable potential upside of 186.21%. As a biopharmaceutical company, Ultragenyx is dedicated to..

Premier, Inc. (PINC) Investor Outlook: Navigating Healthcare with a 3.02% Dividend Yield

Premier, Inc. (NASDAQ: PINC), a prominent player in the healthcare sector, operates at the intersection of health information services, providing innovative solutions through its dual segments: Supply Chain Services and..

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Unpacking a 22.44% Potential Upside in the Medical Instruments Sector

LeMaitre Vascular, Inc. (NASDAQ: LMAT) stands as a beacon of innovation in the medical instruments and supplies industry. Operating within the healthcare sector, this Massachusetts-based company is making waves with..

Arrowhead Pharmaceuticals (ARWR) Stock Analysis: Exploring a 37% Upside Potential

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is drawing significant attention in the biotechnology sector as it continues to forge a promising path in developing innovative treatments for complex diseases. With a..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds